GSK takes fight to AZ/Merck & Co with first-line ovarian cancer approvalThe FDA has approved GlaxoSmithKline’s Zejula as first-line maintenance treatment for women with platinum-responsive ovarian cancer, competing against Share XGSK takes fight to AZ/Merck & Co with first-line ovarian cancer approvalhttps://pharmaphorum.com/news/fda-approves-gsks-zejula/
GSK starts 2020 on a high, but warns of tougher times aheadGlaxoSmithKline saw its sales surge in the first three months of the year, with the coronavirus pandemic giving Share XGSK starts 2020 on a high, but warns of tougher times aheadhttps://pharmaphorum.com/news/gsk-starts-2020-on-a-high-but-warns-of-tougher-times-ahead/
PARP & DNA Damage Response Inhibitors Summit 2020PARP DNA Damage Response Summit DDR Synthetic Lethality Share XPARP & DNA Damage Response Inhibitors Summit 2020https://pharmaphorum.com/events/parp-dna-damage-response-inhibitors-summit-2020/
ESMO 2019 – new data could unlock bigger market for PARP inhibitorsAstraZeneca and GlaxoSmithKline could both benefit from new data that should widen the market for PARP inhibitors as Share XESMO 2019 – new data could unlock bigger market for PARP inhibitorshttps://pharmaphorum.com/news/esmo-2019-new-data-could-unlock-bigger-market-for-parp-inhibitors/
As ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian cancer dataGlaxoSmithKline and AstraZeneca will go head-to-head with new data on their PARP inhibitor drugs this weekend, as the Share XAs ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian cancer datahttps://pharmaphorum.com/news/as-esmo-opens-its-doors-gsk-and-az-prep-all-comer-ovarian-cancer-data/
Relief for GSK as Tesaro’s Zejula hits the mark in ovarian cancerGlaxoSmithKline raised eyebrows last year when it paid $5.1 billion for Tesaro and its PARP inhibitor Zejula, amid Share XRelief for GSK as Tesaro’s Zejula hits the mark in ovarian cancerhttps://pharmaphorum.com/news/relief-for-gsk-as-tesaros-zejula-hits-the-mark-in-ovarian-cancer/
Tesaro stock rockets as rumours of Roche takeover aboundShares in US biotech Tesaro peaked this week amid speculation that Roche is making plans to buy it. Share XTesaro stock rockets as rumours of Roche takeover aboundhttps://pharmaphorum.com/news/tesaro-stock-rockets-roche-takeover-abound/